• LAST PRICE
    0.0800
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.0800/ 7
  • Ask / Lots
    0.0900/ 32
  • Open / Previous Close
    0.0850 / 0.0800
  • Day Range
    Low 0.0800
    High 0.0850
  • 52 Week Range
    Low 0.0500
    High 0.1650
  • Volume
    20,176
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.08
TimeVolumeAGN
02:05 ET70000.085
03:01 ET130000.08
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
CanadaAGN
Algernon Pharmaceuticals Inc
2.2M
-0.4x
---
CanadaPSYG
Psyence Group Inc
2.1M
0.0x
---
CanadaRVV
Revive Therapeutics Ltd
2.1M
-0.7x
---
CanadaNIRV
Nirvana Life Sciences Inc
2.5M
-2.3x
---
CanadaPSYB.H
PsyBio Therapeutics Corp
1.3M
-0.3x
---
CanadaCVM.H
CVR Medical Corp
2.0M
-0.6x
---
As of 2024-11-13

Company Information

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

Contact Information

Headquarters
400 - 601 WEST BROADWAYVANCOUVER, BC, Canada V5Z 4C2
Phone
604-398-4175
Fax
604-646-1553

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.2M
Revenue (TTM)
$0.00
Shares Outstanding
27.3M
Algernon Pharmaceuticals Inc does not pay a dividend.
Beta
-0.33
EPS
$-0.19
Book Value
$0.09
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.